title: Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
abstract: Thirty patients suffering from essential hypertension were treated successively with placebo, hydralazine alone, and pindolol (Viskén) combined with hydralazine. As compared to placebo hydralazine brought about a statistically significant reduction in blood pressure and an increase in pulse rate; palpitation was an irritating side-effect. Combining hydralazine and pindolol caused an additional fall in blood pressure (2 p less than 0.001) and the pulse rate decreased (2 p less than 0.001). This combination treatment had a favourable effect on the palpitation and angina pectoris also.
mesh_terms: D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D010869:Pindolol / Q000627:therapeutic use*; D010919:Placebos; D011674:Pulse / Q000187:drug effects
chemical_list: D010919:Placebos; D006830:Hydralazine; D010869:Pindolol